Differentiating Between Brain Hemorrhage and Contrast
- Disease/Condition
- Ischemic Stroke
- Study type
- Observational
- Primary sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Phase
- N/A
- Start date
- Sep 01, 2023
- End date
- Dec 01, 2024
- Enrollment
- 500 participants
Develop a deep learning model to differentiate brain hemorrhage from contrast agent extravasation, and evaluate the model performance and generalization ability
The goal of this observational study is to use artificial intelligence to differentiate
 cerebral hemorrhage from contrast agent extravasation after mechanical revascularization in
 ischemic stroke.
 
 The main question it aims to answer is: Whether artificial intelligence can help
 differentiate brain hemorrhage from contrast agent extravasation.
 
 Patients with intracranial high-density lesions on CT scans within 24h after mechanical
 revascularization will be included. Expected to enroll 500 patients. The type of high-density
 lesion is determined according to dual-energy CT images or follow-up images. Patients will be
 divided into training group, validation and testing groups by stratified random sampling
 (6:2:2). After the images and the image labels are obtained, deep learning artificial
 intelligence will be used to learn the image characteristics and establish a diagnostic
 model, and the model performance and generalization ability will be evaluated.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06032819
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06032819 through Pure Global AI's free database. This phase not specified trial is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and is currently Not yet recruiting. The study focuses on Ischemic Stroke. Target enrollment is 500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.